PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
32 hedge funds and large institutions have $38.5M invested in PLx Pharma Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 7 reducing their positions, and 7 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 7
51% more capital invested
Capital invested by funds: $25.5M → $38.5M (+$13M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 33 → 32 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.11M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$357K |
| 3 |
1CM
1492 Capital Management
Milwaukee,
Wisconsin
|
+$318K |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
+$287K |
| 5 |
TCM
Timpani Capital Management
Milwaukee,
Wisconsin
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$444K |
| 2 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$385K |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$291K |
| 4 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$246K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$244K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BIM
26
BlackRock Investment Management
Wilmington,
Delaware
| $14K | – | – | – |
|
27
UBS Group
Zurich,
Switzerland
| $9K | +$1.36K | +14 | +22% |
|
|
FANJ
28
Financial Architects (New Jersey)
Marlton,
New Jersey
| $5K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $4K | +$390 | +4 | +11% |
|
30
Bank of America
Charlotte,
North Carolina
| $3K | +$1.66K | +17 | +213% |
|
31
JP Morgan Chase
New York
| $3K | +$2.44K | +25 | New |
|
|
FMA
32
FNY Managed Accounts
New York
| $2.17K | +$1.85K | +19 | New |
|
|
BC
33
Broadfin Capital
New York
| – | -$444K | -5,597 | Closed |
|
|
FPC
34
Falcon Point Capital
San Francisco,
California
| – | -$385K | -4,854 | Closed |
|
|
BCM
35
Bridgeway Capital Management
Houston,
Texas
| – | -$244K | -3,075 | Closed |
|
36
US Bancorp
Minneapolis,
Minnesota
| – | -$40K | -506 | Closed |
|
37
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$15K | -194 | Closed |
|
38
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$6K | -73 | Closed |
|
|
ASN
39
Advisory Services Network
Atlanta,
Georgia
| – | -$3K | -38 | Closed |
|
PLXP Hedge Fund Activity: Q3 2016 in Review
32 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2016, worth a combined $38.5M — up 51% from $25.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PLXP and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 16 added.
The largest buyer was Great Point Partners, adding an estimated $1.11M. The largest seller was Broadfin Capital, exiting entirely with an estimated $444K sold.
- 32 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2016, down from 33 in Q2 2016.
- Funds reported $38.5M of PLx Pharma Inc. Common Stock stock for Q3 2016, up 51% quarter-over-quarter.
- 6 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2016 and 7 closed out, a net change of -1 holder.
- The largest PLx Pharma Inc. Common Stock buyer in Q3 2016 was Great Point Partners, an estimated $1.11M added.
- The largest PLx Pharma Inc. Common Stock seller in Q3 2016 was Broadfin Capital, an estimated $444K sold.
Based on aggregated 13F filings for Q3 2016.